» Articles » PMID: 16935100

Long-term Survival After Non-small Cell Lung Cancer Surgery: Development and Validation of a Prognostic Model with a Preoperative and Postoperative Mode

Overview
Date 2006 Aug 29
PMID 16935100
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: At present, there is no prognostic model that is specific for prediction of survival after non-small cell lung cancer surgery. We aimed to develop a prognostic model that can be used to estimate the postoperative survival of individual patients.

Methods: A total of 766 patients underwent resection for primary non-small cell lung cancer. Comorbid conditions were scaled according to the Charlson comorbidity index (CCI). Cox proportional hazard analyses were used to determine risk factors for survival. A prognostic model for survival with a preoperative and postoperative mode was established. Performance of the prognostic model, the CCI, and pathologic tumor stage were quantified by a concordance statistic to indicate discriminative ability.

Results: The factors associated with an impaired survival were male sex, age, chronic obstructive pulmonary disease, congestive heart failure, any prior tumor, moderate-to-severe renal disease (preoperative and postoperative mode), clinical tumor stage (preoperative mode), type of resection, and pathologic tumor stage (postoperative mode). The discriminative performance was poor for the CCI (c = 0.55), better for pathologic tumor stage (c = 0.60) and for the preoperative mode (c = 0.61), and best for the postoperative mode (c = 0.65). The discriminative performance of the postoperative mode was better than the discriminative performance of the CCI (P < .0001), the preoperative mode (P < .0002), and pathologic tumor stage (P < .0001). The discriminative performance of the preoperative mode was better than the discriminative performance of the CCI (P < .0001) and similar (P = .90) to a model that only included pathologic tumor stage.

Conclusions: The prognostic model, particularly the postoperative mode, successfully estimates long-term survival of individual patients and could help clinicians in clinical decision-making and treatment tailoring.

Citing Articles

A Nomogram to Predict the Overall Survival of Patients With Resected T1-2N0-1M0 Non-Small Cell Lung Cancer and to Identify the Optimal Candidates for Adjuvant Chemotherapy in Stage IB or IIA Non-Small Cell Lung Cancer Patients.

Wang W, Zhou J Cancer Control. 2023; 30:10732748231197973.

PMID: 37703536 PMC: 10501081. DOI: 10.1177/10732748231197973.


The association of postoperative radiotherapy with survival in resected N2 non-small cell lung cancer.

Zeng Y, Liu J, Wan M, Li Q, Liu H, Cui F J Thorac Dis. 2023; 15(1):42-53.

PMID: 36794137 PMC: 9922593. DOI: 10.21037/jtd-22-772.


Development and validation of a nomogram for predicting survival time and making treatment decisions for clinical stage IA NSCLC based on the SEER database.

Xu B, Ye Z, Zhu L, Xu C, Lu M, Wang Q Front Med (Lausanne). 2023; 9:972879.

PMID: 36619647 PMC: 9811385. DOI: 10.3389/fmed.2022.972879.


Establishment and validation of a novel prognostic model for non-virus-related hepatocellular carcinoma.

Jiang Y, Chen S, Wu Y, Qu Y, Jia L, Xu Q Cancer Cell Int. 2022; 22(1):300.

PMID: 36184588 PMC: 9528074. DOI: 10.1186/s12935-022-02725-5.


A Novel Nomogram including AJCC Stages Could Better Predict Survival for NSCLC Patients Who Underwent Surgery: A Large Population-Based Study.

Shang X, Yu H, Lin J, Li Z, Zhao C, Sun J J Oncol. 2020; 2020:7863984.

PMID: 32565807 PMC: 7256774. DOI: 10.1155/2020/7863984.